Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of INL1 in Patients With Heart Failure and Reduced Ejection Fraction

NCT03875183 is registered in ClinicalTrials.gov with Innolife Co., Ltd. as lead sponsor.

NCT NCT03875183
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03875183 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of INL1 in Patients With Heart Failure and Reduced Ejection Fraction
Lead sponsor
Innolife Co., Ltd.
Phase
Phase 2
Overall status
Unknown status
Start date
January 20, 2020
Completion date
January 31, 2023
Enrollment
200 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure, reduced ejection fraction